Literature DB >> 18363743

Varicella zoster virus glycoprotein E-specific CD4+ T cells show evidence of recent activation and effector differentiation, consistent with frequent exposure to replicative cycle antigens in healthy immune donors.

G N Malavige1, L Jones, A P Black, G S Ogg.   

Abstract

Varicella zoster viru (VZV)-specific T cell responses are believed to be vital in recovery from primary VZV infection and also in the prevention of viral reactivation. While glycoprotein E (gE) is the most abundant and one of the most immunogenic proteins of the virus, there are no data addressing potential T cell epitopes within gE, nor the phenotype of specific T cells. Using interferon gamma enzyme-linked immunospot assays and intracellular cytokine assays, we identified gE-specific immune responses in 20 adult healthy immune donors which were found to be dominated by the CD4+ subset of T cells. We characterized three immune dominant epitopes within gE restricted through DRB1*1501, DRB1*07 and DRB4*01, and used DRB1*1501 class II tetrameric complexes to determine the ex vivo frequency and phenotype of specific T cells. In healthy immune donors, the cells were largely positive for CCR7, CD28 and CD27, but expressed variable CD62L and low levels of cutaneous lymphocyte associated antigen with evidence of recent activation. In summary, we show that circulating gE-specific CD4+ T cells are detected at a relatively high frequency in healthy immune donors and show evidence of recent activation and mixed central and effector memory phenotype. These data would be compatible with frequent exposure to replicative cycle antigens in healthy donors and are consistent with a role for gE-specific CD4+ T cells in the control of viral replication.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18363743      PMCID: PMC2453195          DOI: 10.1111/j.1365-2249.2008.03633.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  48 in total

1.  Disseminated infection with varicella-zoster virus vaccine strain presenting as hepatitis in a child with adenosine deaminase deficiency.

Authors:  F Ghaffar; K Carrick; B B Rogers; L R Margraf; K Krisher; O Ramilo
Journal:  Pediatr Infect Dis J       Date:  2000-08       Impact factor: 2.129

2.  Memory cytotoxic T cell responses to viral tegument and regulatory proteins encoded by open reading frames 4, 10, 29, and 62 of varicella-zoster virus.

Authors:  Ann M Arvin; Margaret Sharp; Melinda Moir; Paul R Kinchington; Majid Sadeghi-Zadeh; William T Ruyechan; John Hay
Journal:  Viral Immunol       Date:  2002       Impact factor: 2.257

3.  Development and validation of a gamma interferon ELISPOT assay for quantitation of cellular immune responses to varicella-zoster virus.

Authors:  J G Smith; X Liu; R M Kaufhold; J Clair; M J Caulfield
Journal:  Clin Diagn Lab Immunol       Date:  2001-09

4.  Disseminated vaccine strain varicella as the acquired immunodeficiency syndrome-defining illness in a previously undiagnosed child.

Authors:  J M Kramer; P LaRussa; W C Tsai; P Carney; S M Leber; S Gahagan; S Steinberg; R A Blackwood
Journal:  Pediatrics       Date:  2001-08       Impact factor: 7.124

5.  Frequencies of memory T cells specific for varicella-zoster virus, herpes simplex virus, and cytomegalovirus by intracellular detection of cytokine expression.

Authors:  H Asanuma; M Sharp; H T Maecker; V C Maino; A M Arvin
Journal:  J Infect Dis       Date:  2000-03       Impact factor: 5.226

6.  Direct enumeration of Borrelia-reactive CD4 T cells ex vivo by using MHC class II tetramers.

Authors:  A L Meyer; C Trollmo; F Crawford; P Marrack; A C Steere; B T Huber; J Kappler; D A Hafler
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

Review 7.  Immune evasion as a pathogenic mechanism of varicella zoster virus.

Authors:  A Abendroth; A M Arvin
Journal:  Semin Immunol       Date:  2001-02       Impact factor: 11.130

8.  Effect of viral load on the outcome of herpes zoster.

Authors:  M L Quinlivan; K Ayres; H Ran; S McElwaine; M Leedham-Green; F T Scott; R W Johnson; J Breuer
Journal:  J Clin Microbiol       Date:  2007-09-12       Impact factor: 5.948

9.  The requirement of varicella zoster virus glycoprotein E (gE) for viral replication and effects of glycoprotein I on gE in melanoma cells.

Authors:  Chengjun Mo; Jay Lee; Marvin Sommer; Charles Grose; Ann M Arvin
Journal:  Virology       Date:  2002-12-20       Impact factor: 3.616

10.  Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections.

Authors:  Victor Appay; P Rod Dunbar; Margaret Callan; Paul Klenerman; Geraldine M A Gillespie; Laura Papagno; Graham S Ogg; Abigail King; Franziska Lechner; Celsa A Spina; Susan Little; Diane V Havlir; Douglas D Richman; Norbert Gruener; Gerd Pape; Anele Waters; Philippa Easterbrook; Mariolina Salio; Vincenzo Cerundolo; Andrew J McMichael; Sarah L Rowland-Jones
Journal:  Nat Med       Date:  2002-04       Impact factor: 53.440

View more
  35 in total

Review 1.  Herpes zoster and the search for an effective vaccine.

Authors:  N Arnold; I Messaoudi
Journal:  Clin Exp Immunol       Date:  2016-07-25       Impact factor: 4.330

2.  Immunogenicity of varicella zoster virus glycoprotein E DNA vaccine.

Authors:  Lidao Bao; Guomin Wei; Hongmei Gan; Xianhua Ren; Ruilian Ma; Y I Wang; Haijun Lv
Journal:  Exp Ther Med       Date:  2016-02-19       Impact factor: 2.447

3.  Identification of serotype-specific T cell responses to highly conserved regions of the dengue viruses.

Authors:  G N Malavige; S McGowan; V Atukorale; M Salimi; M Peelawatta; N Fernando; S D Jayaratne; G Ogg
Journal:  Clin Exp Immunol       Date:  2012-05       Impact factor: 4.330

Review 4.  Varicella Virus Vaccination in the United States.

Authors:  Jana Shaw; Anne A Gershon
Journal:  Viral Immunol       Date:  2017-11-27       Impact factor: 2.257

Review 5.  The life cycle of a T cell after vaccination - where does immune ageing strike?

Authors:  C Kim; F Fang; C M Weyand; J J Goronzy
Journal:  Clin Exp Immunol       Date:  2016-08-15       Impact factor: 4.330

6.  Varicella-zoster virus glycoproteins B and E are major targets of CD4+ and CD8+ T cells reconstituting during zoster after allogeneic transplantation.

Authors:  Patrick Kleemann; Eva Distler; Eva M Wagner; Simone Thomas; Sebastian Klobuch; Steffi Aue; Elke Schnürer; Hansjörg Schild; Matthias Theobald; Bodo Plachter; Stefan Tenzer; Ralf G Meyer; Wolfgang Herr
Journal:  Haematologica       Date:  2011-12-29       Impact factor: 9.941

7.  Tracking antigen-specific T-cells during clinical tolerance induction in humans.

Authors:  Aamir Aslam; Hsien Chan; David A Warrell; Siraj Misbah; Graham S Ogg
Journal:  PLoS One       Date:  2010-06-09       Impact factor: 3.240

8.  Immune Responses to Varicella-Zoster Virus Glycoprotein E Formulated with Poly(Lactic-co-Glycolic Acid) Nanoparticles and Nucleic Acid Adjuvants in Mice.

Authors:  Yunfei Wang; Jialong Qi; Han Cao; Cunbao Liu
Journal:  Virol Sin       Date:  2020-08-05       Impact factor: 4.327

9.  Simian varicella virus infection of rhesus macaques recapitulates essential features of varicella zoster virus infection in humans.

Authors:  Ilhem Messaoudi; Alexander Barron; Mary Wellish; Flora Engelmann; Alfred Legasse; Shannon Planer; Don Gilden; Janko Nikolich-Zugich; Ravi Mahalingam
Journal:  PLoS Pathog       Date:  2009-11-13       Impact factor: 6.823

10.  IE63-specific T-cell responses associate with control of subclinical varicella zoster virus reactivation in individuals with malignancies.

Authors:  G N Malavige; L T Rohanachandra; L Jones; L Crack; M Perera; N Fernando; D Guruge; G S Ogg
Journal:  Br J Cancer       Date:  2010-01-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.